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CLINICAL INVESTIGATION
Contrasting effects of potassium citrate and sodium citrate
therapies on urinary chemistries and crystallization
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Contrasting effects of potassium citrate and sodium citrate therapies on
urinary chemistries and crystallization of stone-forming salts. Effects of
potassium citrate therapy (60 mEq/day) on urinary chemistries and
crystallization were compared to those of sodium citrate treatment in
five patients with uric acid lithiasis. Both alkali treatments significantly
increased urinary pH (P < 0.001), from 5.35 0.18 so to 6.68 0.14 for
potassium citrate and 6.73 0.20 for sodium citrate. During
potassium citrate therapy, urinary calcium significantly declined from
154 47 mg/day to 99 23 mg/day (P < 0.01) and urinary citrate rose
from 398 119 mg/day to 856 103 mg/day (P < 0.001). The urinary
saturation (activity product ratio) of calcium oxalate decreased from
3.21-fold to 1.69-fold saturation (P < 0.01), and the inhibitor activity
against calcium oxalate precipitation (formation product ratio) signifi-
cantly increased. However, sodium citrate therapy did not significantly
decrease urinary calcium (to 139 24 mg/day), although it increased
urinary citrate substantially (to 799 89 mg/day, P < 0.01). Urinary
environment became supersaturated with respect to brushite (calcium
phosphate) and monosodium urate. The inhibitor activity against calci-
um oxalate precipitation was not significantly altered for the whole
group; in two patients, it decreased by more than 30%. The results
indicate that (1) both alkali therapies are equally effective in preventing
uric acid stone formation because of their ability to increase urinary pH,
and (2) potassium citrate may prevent the complication of calcium
nephrolithiasis in patients with uric acid stones, whereas sodium citrate
may not.
Effets opposes de traitements par le citrate de potassium et le citrate de
sodium sur les paramètres biochimiques et Ia cristallisation urinaires des
sels Iithogenes. Les effets d'un traitement par Ic citrate de potassium (60
mEq/jour) sur les paramètres biochimiques et Ia cristallisation urinaires
été compares a ceux d'un traitement par le citrate de sodium chez cinq
malades atteints de lithiase urique. Ces deux traitements alcalinisants
ont augmenté significativement Ic pH urinaire (P < 0.001), de 5.35
0.18 SD a 6.68 0.14 pour Ic citrate de potassium, et 6.73 0.20 pour Ic
citrate de sodium. Pendant Ic traitement par le citrate de potassium, Ia
calciurie a diminué significativement de 154 47 mg/jour a 99 23
mg/jour (P < 0.01) et Ic citrate urinaire s'est élevé de 398 119mg/jour
a 856 103 mg/jour (P < 0.001). La saturation urinaire (rapport de
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produit d'activité) de l'oxalate de calcium a diminué d'une saturation de
3.21 fois a une saturation de 1.69 fois (P <0.01), et I'activité inhibitrice
de Ia precipitation d'oxalate de calcium (rapport de produit de forma-
tion) a augmenté significativement. Toutefois, le traitement par Ic
citrate de potassium n'a pas diminué significativement Ia calciurie (a 139
24 mg/jour), bien qu'elle ait augmenté Ic citrate urinaire de facon
substantielle (a 799 89 mg/jour, p < 0.01). L'environnement urinaire
est devenu sursaturC en brushite (phosphate de calcium) et en urate
monosodique. L'activité inhibitrice de Ia precipitation d'oxalate de
calcium n'Ctait pas modifiée de facon significative pour le groupe entier;
chez deux malades dIe a diminuC de plus de 30%. Ces résultats
indiquent que (1) les deux traitements alcalinisants sont aussi efficaces
l'un que l'autre pour prCvenir La formation de calculs d'acide urique en
raison de leur capacité a augmenter Ic pH urinaire, et (2) le citrate de
potassium pourrait prévenir Ia complication a type de lithiase rénale
calcique chez les malades ayant des calculs d'acide urique, cc que ne
pourrait faire Ic citrate de sodium.
An important determinant for the formation of uric acid
stones is the passage of uncommonly acid urine. The urinary
pH in patients with uric acid lithiasis is typically less than the
dissociation constant (pKa) of uric acid of 5.47 [1]; thus, their
urinary environment is supersaturated with respect to uric acid.
Because uric acid is more soluble at a higher pH, it has been
customary to recommend alkalinization of urine for manage-
ment of uric acid nephrolithiasis [2]. Sodium salts of bicarbon-
ate and citrate have sometimes been used as alkalinizing agents.
Although it may cause dissolution or inhibit formation of uric
acid stones, sodium alkali therapy may be complicated by the
development of calcium-containing renal stones (calcium phos-
phate and/or calcium oxalate) [3—6]. However, our preliminary
study indicated that potassium alkali therapy may avert such a
complication in uric acid lithiasis [4]. Moreover, the treatment
with potassium citrate was shown to correct hypocitraturia (low
urinary citrate), a defect frequently encountered in calcium
nephrolithiasis [7—17]. This finding suggested that potassium
alkali may also be useful in the management of calcium urolith-
iasis associated with hypocitraturia.
These circumstances led us to compare in detail the biochem-
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ical and physicochemical effects of potassium citrate therapy
from those of sodium citrate therapy. It will be shown that
potassium citrate is more effective than sodium citrate in
inhibiting the crystallization of calcium oxalate in urine.
Methods
Experimental subjects. Five patients with documented uric
acid lithiasis who developed the complication of calcium stones
on sodium alkali treatment participated in the study. The
patients ranged in age from 42 to 69 years. All were men. All
subjects had adequate endogenous creatinine clearance, rang-
ing from 75 to 130 mI/mm. None of the participating subjects
suffered from hyperkalemia, fluid retention, urinary tract infec-
tion, or urinary tract obstruction during the study. Only one
patient suffered gout. None had chronic diarrheal syndrome.
The study was approved by the human experimentation com-
mittee, and informed consent was obtained from each of the
participating subjects.
Study protocol. The study comprised three phases, consisting
of control phase (no drug), potassium citrate phase, and sodium
citrate phase, conducted randomly. The dosage of the two
forms of alkali were the same (60 mEq/day in three divided
doses orally). All other drugs were withheld during the study.
Each phase was 4 weeks long. After 3 weeks of stabilization in
an outpatient setting, patients underwent an inpatient evalua-
tion during the last week.
During each inpatient evaluation, subjects were maintained
on a constant metabolic diet with a daily composition of 400 mg
calcium, 800 mg phosphorus, 100 mEq sodium, 60 mEq potassi-
um, and sufficient fluid to ensure approximately 2 liters of urine
daily for the entire study period of 6 days. After 3 days of
stabilization, urine samples were collected daily in 24-hr pools
during the last 3 days for total volume, pH, calcium, oxalate,
phosphorus, sodium, potassium, magnesium, ammonium, ci-
trate, sulfate, and uric acid; relative saturation ratio (RSR) of
monosodium urate and monopotassium urate; activity product
ratio (APR) of brushite (CaHPO4 • 2H20) and calcium oxalate;
and formation product ratio (FPR) of brushite and calcium
oxalate.
Analytical procedures. Urinary calcium and magnesium were
determined by atomic absorption spectrophotometry and sodi-
um and potassium by flame photometry. Phosphorus was
measured by the colorimetric technique of Chen et al [18],
oxalate by the method of Hodgkinson and Williams [19], sulfate
by turbidimetric procedure of Ma and Chan [20], and uric acid
by the enzymatic method of Liddle, Seegmiller, and Laster [21].
Citrate was determined enzymatically with kits from Boeh-
ringer-Mannheim Biochemicals (Indianapolis, Indiana), which
gave a 3 and 6%, intra- and interassay variation, respectively.
This enzymatic method was found to be comparable in yield to
the pentabromacetone colorimetric method of Beutler and Yeh
[22]. Citrate values were within 10% agreement between these
two methods. Ammonium was measured colorimetrically by a
method adapted from Chaney and Marbach [23].
Crystallization studies. Methods for the assessment of uri-
nary crystallization were previously reported [24—27] and will
be briefly described here.
The activity product ratio represented the state of saturation
with respect to the solid phase [24]. The urine sample was
incubated with an excess of solid phase (brushite or calcium
oxalate) to steady state. The ratio of activity products in the
original sample and the ambient fluid after incubation to steady-
state with the solid phase, gave a quantitative measure of
saturation, where a value of I indicated saturation, greater than
1 supersaturation and less than I undersaturation.
The urinary saturation with respect to urate salts was estimat-
ed from the relative saturation ratio. The RSR represented the
ratio of the activity product in the original sample and the
thermodynamic solubility product [27]. The RSR of monosodi-
um urate was previously shown to correspond closely with APR
[25].
The formation product ratio indicated the limit of metastabil-
ity or minimum supersaturation required for spontaneous nucle-
ation [24]. Strictly, it represented heterogenous nucleation by
naturally occurring nuclei in urine. To samples rendered devoid
of cellular debris and crystalline material by filtration (Millipore
0.22 m, Millipore Corp., Bedford, Massachusetts), a solution
of calcium chloride or sodium oxalate was added in increasingly
large amounts to cause precipitation of calcium phosphate or
calcium oxalate, respectively. The minimum activity product
ratio that permitted precipitation at 3 hr represented the FPR.
Thus, an increased FPR reflected increased inhibition of
crystallization.
Statistical analysis. The paired t test was used to test the
significance of changes in measured parameters between con-
trol and treatment phases.
Results
Effect of alkali therapy on urinary chemistries. In five pa-
tients with uric acid lithiasis, urinary pH rose significantly
during both alkali treatments (Table I). The rise in urinary pH
occurring from potassium citrate therapy was equivalent to that
resulting from sodium citrate therapy. Urinary calcium declined
significantly during potassium citrate therapy but not during
sodium citrate treatment (Table 1 and Fig. I). Urinary calcium
during potassium citrate therapy was significantly lower than
during sodium citrate therapy. Urinary sodium increased signif-
icantly during sodium citrate treatment and urinary potassium
rose significantly during potassium citrate treatment (Table I).
Urinary ammonium decreased significantly during both alkali
phases (Table 1); the decline was more prominent during
potassium citrate therapy. Urinary citrate increased significant-
ly during both alkali phases; the rise was greater during
potassium citrate treatment than during sodium citrate therapy
although the difference was not significant (Table I and Fig. I).
There were small or no significant changes in urinary total
volume, oxalate, phosphorus, magnesium, sulfate, or uric acid
between the three phases (Table 1). Moreover, no significant
change in endogenous creatinine clearance occurred during
alkali treatment.
Effect of alkali therapy on urinary crystallization. Both alkali
therapies caused a significant decline in urinary APR of calcium
oxalate; however, the decline was more prominent during
potassium citrate therapy than during sodium alkali therapy
(Table 1, Fig. 2). Thus, urinary saturation of calcium oxalate
declined during alkali therapies, more so when potassium
citrate was given. Urinary APR of brushite increased during
both alkali therapies; the rise was more prominent during
sodium citrate therapy (Table 1). Urinary environment became
supersaturated (APR > 1) with respect to brushite during
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Table 1. Effect of alkali therapies on urinary chemistries and crystallization in patients with uric acid lithiasis"
Control Potassium citrate Sodium citrate
Total volume, mi/day 2456 290 2525 359 2669 296
pH 5.35 0.18 6.68 0.l4 6.73 0.20e
Calcium, mg/day 154 47 99 23d 139 24d
Oxalate, mg/day 28.6 2.3 28.6 2.7 31.8 44c(
Phosphorus, mg/day 680 143 657 109 663 78
Sodium, mEq/day 104 33 88 26 166 30°
Potassium, mEq/day 42 II 114 l6 48 9c
Magnesium, mg/day 85 22 88 14 96 16
Ammonium, mEq/day 30.1 7.8 9.7 3.6 12.2 3.8
Citrate, mg/day 398 119 856 103c 799 89
Sulfate, msi/day 18.9 7.3 17.5 5.6 20.3 4.1
Uric acid, mg/day 417 121 522 171 512 132
Activity product ratio
Calcium oxalate 3.21 0.96 1.69 0.76d 2.21 0.63cd
Brushite 0.04 0.03 0.74 0.22w 1.17 0.44'
Formation product ratio
Calcium oxalate 16.1 5.6 22.2 6.6 14.1 5.3
Brushite 2.62 0.87 2.53 0.52 3.07 0.25
Relative saturation ratio
Monosodium urate 0.51 0.20 0.95 0.33 1.45 0.44dd
Monopotassiumurate 0.05 0.019 0.33 0.07d 0.12 0.04
Values are presented as mean SD. ' There is a significant difference between each alkali and control phase, determined by the paired i' test; it
is shown by P <Øo5,' P <0.01 and P <0.001. The significant differences between potassium citrate and sodium citrate phases are indicated in
parentheses by the same footnotes.
sodium alkali treatment, whereas it remained undersaturated
when potassium citrate was given.
The urinary FPR of calcium oxalate rose significantly during
oral potassium citrate treatment (Table I, Fig. 2). Thus, sponta-
neous precipitation of calcium oxalate commenced at a higher
level of supersaturation when potassium was given. However,
FPR of calcium oxalate did not change significantly during
sodium citrate therapy. The difference in FPR between the two
alkali phases was significant. In two of five patients. FPR
decreased by more than 30% (Fig. 2): thus, spontaneous
precipitation was facilitated in some patients. The FPR of
brushite was not significantly altered by either treatment.
The saturation of monosodium urate (RSR) rose significantly
during both alkali phases, more so during sodium citrate
therapy (Table 1). The urinary environment became supersatu-
rated with respect to monosodium urate during sodium citrate
therapy, but remained undersaturated when potassium citrate
was given. The saturation of monopotassium urate (RSR)
increased significantly during both alkali treatments, but more
so during potassium citrate therapy.
Discussion
The current study discloses that both potassium citrate and
sodium citrate should be effective in the prevention of uric acid
lithiasis. The five patients with documented uric acid lithiasis
initially passed uncommonly acid urine (pH < pK, for uric acid)
[28]. Thus, their urinary environment supported the crystalliza-
tion of uric acid. Treatment with either alkali significantly
raised their urinary pH to a range where uric acid is more
soluble.
However, the two forms of alkali may exert different actions
with respect to complication or prevention of calcium nephro-
lithiasis. Five patients with uric acid stones were evaluated to
compare the ability of potassium citrate therapy from that of
sodium citrate treatment in preventing the complication of
calcium nephrolithiasis. These patients gave a history of pas-
sage of a mixture of uric acid and calcium stones (calcium
phosphate and/or calcium oxalate) or predominantly calcium
stones, coinciding with alkali therapy (sodium bicarbonate or
sodium citrate).
When sodium citrate was given, no significant reduction in
urinary calcium ensued, despite the well-known effect of alkali
therapy in lowering calcium excretion [29, 30]. The "hypocal-
ciuric" action of alkali therapy was apparently attenuated by
the reduction of renal calcium reabsorption occurring from
sodium load given with alkali [311. Thus, urinary saturation of
calcium oxalate decreased modestly during sodium alkali thera-
py. Although urinary calcium did not change substantially.
urinary pH increased markedly during sodium citrate therapy.
The resulting increased dissociation of phosphate led to an
increased urinary saturation of calcium phosphate (brushite).
Moreover, urinary saturation of monosodium urate rose be-
cause of increased dissociation of uric acid (from the rise in
urinary pH) and since more sodium was delivered to urine (from
ingested sodium with alkali). The urinary environment became
supersaturated with respect to brushite and monosodium urate
when sodium citrate was given.
During sodium citrate therapy, urinary citrate increased
nearly twofold. Although citrate is a recognized inhibitor of
calcium oxalate crystallization [32, 33], no significant change
was observed in the urinary inhibitor activity as assessed by the
FPR of calcium oxalate for the whole group of five patients.
Two patients had a substantial reduction in the FPR, a finding
suggesting that spontaneous precipitation of calcium oxalate
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Fig. 1. Effect of potassium and sodium citrate therapies on urinary
calcium and citrate in patients with uric acid lithiasis. Each line
represents a study in separate patients. Horizontal bars indicate group
means. Significant difference from the control phase is shown by ** for
P < 0.01 and t for P < 0.001.
was facilitated by sodium citrate therapy. Though not conclu-
sively proven, there is some evidence for the scheme indicating
participation of monosodium urate in initiating calcium oxalate
crystallization [26, 34—37]. Since sodium citrate therapy is
accompanied by urinary supersaturation with monosodium
urate, the urate-induced facilitation of calcium oxalate nucle-
ation could have opposed the inhibitory effect of citrate.
The results suggest that sodium citrate does not prevent the
complication of calcium nephrolithiasis when given to patients
with uric acid stones. It might cause this complication because
of increased urinary saturation of calcium phosphate, and in
some patients when the effect of monosodium urate-induced
calcium oxalate crystallization overrides the inhibitory action of
citrate.
In contrast to the action of sodium citrate, potassium citrate
at the same equimolar dosage significantly reduced urinary
calcium excretion. Since additional sodium was not given with
alkali, the hypocalciuric effect of alkali load [29, 30] was
apparently unopposed. Owing principally to the fall in urinary
calcium, urinary saturation of calcium oxalate decreased signifi-
cantly to a greater extent than during sodium citrate therapy.
Moreover, the urinary environment remained undersaturated
with respect to brushite, because the effect of increased phos-
phate dissociation was opposed by a decline in urinary calcium.
The urinary environment also remained undersaturated with
respect to monosodium urate during potassium citrate treat-
ment, since no sodium was delivered with alkali. Potassium
citrate significantly increased the urinary saturation of monopo-
tassium urate owing to increased delivery of potassium to urine
and enhanced dissociation of urate. However, the urinary
Control Potassium Sodium
citrate citrate
Fig. 2. Effect of potassium and sodium citrate therapies on urinary
activity product ratio (APR) and formation product ratio (FPR) of
calcium oxalate in patients with uric acid lithiasis. Symbols are: * for P
<0.05 and ** for P <0.01.
environment was undersaturated with respect to monopotas-
sium urate, probably because of the high solubility of this urate
phase [25].
Potassium citrate significantly increased urinary citrate ex-
cretion, as has been reported with alkali therapy [38—421. The
increase in urinary citrate was more prominent than that
encountered with sodium citrate therapy. Though not signifi-
cant, this difference could be due to the effect of the potassium
ion on citrate metabolism [43—45]. Unlike the situation with
sodium citrate therapy, the rise in urinary citrate occurring from
potassium citrate therapy was accompanied by an inhibition of
the spontaneous precipitation of calcium oxalate (indicated by a
rise in FPR). Thus, the inhibitory effect of citrate was apparent-
ly unopposed by the urate-induced crystallization of calcium
oxalate. This conclusion is supported by the maintenance of
urinary undersaturation with respect to both monosodium urate
and monopotassium urate during potassium citrate therapy.
Even if urinary supersaturation of monopotassium urate had
been achieved, it is unlikely that calcium oxalate crystallization
would have been facilitated. It has been difficult to show the
participation of this urate phase in calcium oxalate crystalliza-
tion [37].
From these considerations, this study suggests that potassi-
um citrate, unlike sodium citrate, may prevent the complication
of calcium oxalate nephrolithiasis when given to patients with
uric acid lithiasis, by reducing urinary saturation and inhibiting
spontaneous precipitation of calcium oxalate. It is acknowl-
edged that a mixture of sodium citrate and potassium citrate has
often been used as an alkalinizing agent in the management of
uric acid stones. Whether the sodium contained in this mixture
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would exert the same "undesirable" effect as pure sodium
citrate used in this study remains to be determined.
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